质子泵抑制剂与组胺-2受体拮抗剂预防应激性溃疡对接受有创机械通气的ICU患者院内死亡率的影响:PEPTIC随机临床试验
PEPTIC试验为在5个国家50个ICU开展的整群交叉随机临床试验,纳入入住ICU 24小时内需有创机械通气的患者,比较首选质子泵抑制剂与首选组胺-2受体拮抗剂两种应激性溃疡预防策略,每个ICU按随机顺序先后使用每种策略6个月。共分析26828例患者,90天院内死亡率在质子泵抑制剂组为18.3%、组胺-2受体拮抗剂组为17.5%(风险比1.05,95%CI 1.00至1.10;绝对风险差0.93个百分点,95%CI -0.01至1.88个百分点;P=0.054),差异未达统计学显著性阈值。临床重要上消化道出血在质子泵抑制剂组为1.3%、组胺-2受体拮抗剂组为1.8%(风险比0.73,95%CI 0.57至0.92;绝对风险差-0.51个百分点,95%CI -0.90至-0.12个百分点;P=0.009)。艰难梭菌感染率及ICU和住院时间两组无显著差异。作者指出研究解读可能受所分配药物交叉使用限制。
要点
- 在需有创机械通气的ICU患者中,首选质子泵抑制剂与首选组胺-2受体拮抗剂预防应激性溃疡的90天院内死亡率分别为18.3%与17.5%,风险比1.05(95%CI 1.00至1.10),未达统计学显著性阈值(P=0.054)。
- 临床重要上消化道出血在质子泵抑制剂组为1.3%、组胺-2受体拮抗剂组为1.8%,风险比0.73(95%CI 0.57至0.92),质子泵抑制剂组较低。
- 艰难梭菌感染率及ICU和住院时间在两组间无显著差异。
- 质子泵抑制剂组报告1例不良事件(过敏反应)。
- 作者指出研究解读可能受所分配药物交叉使用限制:随机分配至质子泵抑制剂的ICU中估计4.1%患者实际接受组胺-2受体拮抗剂,随机分配至组胺-2受体拮抗剂的ICU中估计20.1%患者实际接受质子泵抑制剂。
适用人群与场景
- 5个国家50个ICU中入住ICU 24小时内需有创机械通气的患者,随访90天。
处置流程与药物剂量
- 两种应激性溃疡预防策略比较:首选使用质子泵抑制剂 vs 首选使用组胺-2受体拮抗剂;每个ICU按随机顺序先后使用每种策略6个月。
研究设计与关键结果
- 整群交叉随机临床试验,50个ICU,5个国家,2016年8月至2019年1月;26982例随机,154例退出,26828例分析(平均年龄58岁,标准差17.0;9691例女性,占36.1%);26771例(99.2%)纳入死亡率分析。
- 主要终点90天院内全因死亡率:质子泵抑制剂组13415例中2459例死亡(18.3%),组胺-2受体拮抗剂组13356例中2333例死亡(17.5%);风险比1.05(95%CI 1.00至1.10);绝对风险差0.93个百分点(95%CI -0.01至1.88个百分点);P=0.054。
- 临床重要上消化道出血:质子泵抑制剂组1.3%,组胺-2受体拮抗剂组1.8%;风险比0.73(95%CI 0.57至0.92);绝对风险差-0.51个百分点(95%CI -0.90至-0.12个百分点);P=0.009。
- 艰难梭菌感染率及ICU和住院时间两组无显著差异。
- 质子泵抑制剂组1例患者报告1例不良事件(过敏反应)。
- 交叉使用:随机分配至质子泵抑制剂的ICU中估计4.1%患者实际接受组胺-2受体拮抗剂;随机分配至组胺-2受体拮抗剂的ICU中估计20.1%患者实际接受质子泵抑制剂。
证据类型、等级与局限
- 证据类型:整群交叉随机临床试验。
- 局限:作者指出研究解读可能受所分配药物交叉使用限制。
对床旁实践的改变
- 在需有创机械通气的ICU患者中,首选质子泵抑制剂与首选组胺-2受体拮抗剂预防应激性溃疡的90天院内死亡率分别为18.3%与17.5%,差异未达统计学显著性阈值;临床重要上消化道出血在质子泵抑制剂组较低(1.3% vs 1.8%,风险比0.73,95%CI 0.57至0.92)。
- 作者指出研究解读可能受所分配药物交叉使用限制。
指南或共识出处
- PEPTIC随机临床试验,试验注册号ACTRN12616000481471。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Proton pump inhibitors (PPIs) or histamine-2 receptor blockers (H2RBs) are often prescribed for patients as stress ulcer prophylaxis drugs in the intensive care unit (ICU). The comparative effect of these drugs on mortality is unknown.
OBJECTIVE: To compare in-hospital mortality rates using PPIs vs H2RBs for stress ulcer prophylaxis.
DESIGN, SETTING, AND PARTICIPANTS: Cluster crossover randomized clinical trial conducted at 50 ICUs in 5 countries between August 2016 and January 2019. Patients requiring invasive mechanical ventilation within 24 hours of ICU admission were followed up for 90 days at the hospital.
INTERVENTIONS: Two stress ulcer prophylaxis strategies were compared (preferential use with PPIs vs preferential use with H2RBs). Each ICU used each strategy sequentially for 6 months in random order; 25 ICUs were randomized to the sequence with use of PPIs and then use of H2RBs and 25 ICUs were randomized to the sequence with use of H2RBs and then use of PPIs (13 436 patients randomized by site to PPIs and 13 392 randomized by site to H2RBs).
MAIN OUTCOMES AND MEASURES: The primary outcome was all-cause mortality within 90 days during index hospitalization. Secondary outcomes were clinically important upper gastrointestinal bleeding, Clostridioides difficile infection, and ICU and hospital lengths of stay.
RESULTS: Among 26 982 patients who were randomized, 154 opted out, and 26 828 were analyzed (mean [SD] age, 58 [17.0] years; 9691 [36.1%] were women). There were 26 771 patients (99.2%) included in the mortality analysis; 2459 of 13 415 patients (18.3%) in the PPI group died at the hospital by day 90 and 2333 of 13 356 patients (17.5%) in the H2RB group died at the hospital by day 90 (risk ratio, 1.05 [95% CI, 1.00 to 1.10]; absolute risk difference, 0.93 percentage points [95% CI, -0.01 to 1.88] percentage points; P = .054). An estimated 4.1% of patients randomized by ICU site to PPIs actually received H2RBs and an estimated 20.1% of patients randomized by ICU site to H2RBs actually received PPIs. Clinically important upper gastrointestinal bleeding occurred in 1.3% of the PPI group and 1.8% of the H2RB group (risk ratio, 0.73 [95% CI, 0.57 to 0.92]; absolute risk difference, -0.51 percentage points [95% CI, -0.90 to -0.12 percentage points]; P = .009). Rates of Clostridioides difficile infection and ICU and hospital lengths of stay were not significantly different by treatment group. One adverse event (an allergic reaction) was reported in 1 patient in the PPI group.
CONCLUSIONS AND RELEVANCE: Among ICU patients requiring mechanical ventilation, a strategy of stress ulcer prophylaxis with use of proton pump inhibitors vs histamine-2 receptor blockers resulted in hospital mortality rates of 18.3% vs 17.5%, respectively, a difference that did not reach the significance threshold. However, study interpretation may be limited by crossover in the use of the assigned medication.
TRIAL REGISTRATION: anzctr.org.au Identifier: ACTRN12616000481471.
参考来源
- Young PJ, Bagshaw SM, Forbes AB, et al. Effect of Stress Ulcer Prophylaxis With Proton Pump Inhibitors vs Histamine-2 Receptor Blockers on In-Hospital Mortality Among ICU Patients Receiving Invasive Mechanical Ventilation: The PEPTIC Randomized Clinical Trial. JAMA. 2020. PMID: 31950977. doi:10.1001/jama.2019.22190
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。